Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment
4 Articles
4 Articles
Samsung Biologics announced on the 4th that it received the highest rating in this year's Sustainalytics ESG (Environmental, Social, and Governance) risk assessment. This result is based on an evaluation of non-financial risks and other factors for 16,000 global companies. Samsung Biologics ranked 4th among 842 pharmaceutical companies. Last year, Samsung Biologics received a "Low Risk" rating. This time, it received a "Negligib" rating.
Samsung Biologics Earns Top ESG Risk Grade
Samsung Biologics Plant 4 (provided by Samsung Biologics) Samsung Biologics has been recognized at the highest level for its non-financial risk management capabilities in the global market. Samsung Biologics announced on Nov. 4 that it obtained the top grade, "Negligible," in Sustainalytics' 2026 ESG Risk Rating. Sustainalytics, a subsidiary of Morningstar, evaluates the risks of about 16,000 companies worldwide each year, and the results are u…
占쏙성占쏙옙結占쏙옙占쏙옙占쏙옙占쏙옙 占쌜로뱄옙 환占썸·占쏙옙회占쏙옙占쏙옙占써구占쏙옙(ESG) 占쏙옙占쏙옙크 占쏠가울옙占쏙옙 占쌍삼옙 占쏙옙占쏙옙 占쌨았담옙. 4...
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
